SIGA Technologies Inc. - 10-K Summary (Fiscal Year Ended Dec 31, 2008)
Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2008
Business Overview: SIGA is a biotechnology corporation focused on the research, development, and commercialization of novel anti-infectives for biological warfare defense. The company's lead product candidate is ST-246, an orally administered antiviral for smallpox. The company has no commercial products and relies heavily on U.S. government grants and contracts for revenue.
Key Financial Metrics
| Metric (in thousands) | 2008 | 2007 |
|---|---|---|
| Revenues | $8,066 | $6,699 |
| Net Loss | $(8,599) | $(5,639) |
| Net Loss Per Share (Basic & Diluted) | $(0.25) | $(0.17) |
| Operating Expenses | $16,803 | $14,162 |
| Cash and Cash Equivalents (Year End) | $2,322 | $6,832 |
| Net Cash Used in Operating Activities | $(7,198) | $(5,448) |
| Total Assets | $8,797 | $10,589 |
| Accumulated Deficit | $(70,606) | $(62,006) |
Note: The filing does not provide specific gross margin or operating margin percentages as the company operates at a loss with no commercial product sales.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by 20.1% ($1.4 million) to $8.1 million, driven primarily by a $3.0 million increase in revenue recognized from NIH grants and contracts supporting lead programs. Conversely, revenue from USAF contracts dropped significantly as those specific one-year programs were completed in 2008.
- Expense Increases:
- R&D Expenses: Increased 17% to $11.6 million, primarily due to higher expenditures for clinical and pre-clinical testing of lead drug candidates and increased employee-related costs.
- SG&A Expenses: Increased 24% to $4.6 million, attributed to higher legal fees for litigation support, increased insurance costs, and higher non-cash stock-based compensation.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $4.5 million to $2.3 million, reflecting a net cash burn of $7.2 million from operations, partially offset by $3.2 million in proceeds from the exercise of warrants and options.
Guidance, Outlook, Risks, and Unusual Items
- Outlook & Funding: Management believes existing cash balances combined with anticipated government grants and contracts will support operations beyond the next twelve months. The company expects to continue incurring operating losses for the foreseeable future.
- Major Contracts: In September 2008, SIGA was awarded a five-year, $55.0 million contract from the NIAID for ST-246 development and an additional $20.0 million in supplemental funding for manufacturing validation. These contracts extend through September 2011.
- Legal Contingency: PharmAthene, Inc. filed a lawsuit in December 2006 seeking a license agreement for ST-246 and damages. As of December 31, 2008, discovery was proceeding, and the company could not reasonably estimate a range of loss.
- Key Risks:
- Dependence on U.S. government funding; failure to secure future grants could halt operations.
- Reliance on the FDA "animal rule" for regulatory approval, which carries uncertainty regarding human efficacy.
- Need for additional equity financing to sustain operations if government funding is insufficient.
Investor Verification Checklist
- Government Funding Reliance: Verify the status and renewal likelihood of the $55M and $20M NIAID contracts, as they represent the primary revenue source.
- Cash Runway: Confirm current cash burn rates against the $2.3M cash balance to validate the "beyond 12 months" liquidity claim.
- Legal Exposure: Monitor the status of the PharmAthene litigation regarding ST-246 licensing rights.
- Regulatory Path: Track progress on ST-246 clinical trials and the FDA's acceptance of animal efficacy data under the "animal rule."
- Stock-Based Compensation: Review the impact of non-cash stock-based compensation ($1.0M in 2008) on future expense projections.